Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Kidney (Renal Cell) Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    267 result(s) found for: Kidney (Renal Cell) Cancer. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-001774-15 Sponsor Protocol Number: GR-2013-02357486 Start Date*: 2017-02-09
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: THE ROLE OF 18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS
    Medical condition: kidney cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-005182-31 Sponsor Protocol Number: RCCSCAN Start Date*: 2017-02-23
    Sponsor Name:Lund University
    Full Title: "An exploratory study regarding the use of the biomarker DAT for image diagnosis of clear cell renal cell carcinoma"
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000127-32 Sponsor Protocol Number: ROPETAR Start Date*: 2011-11-03
    Sponsor Name:Werkgroep Immunotherapie Nederland voor Oncologie
    Full Title: A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second lin...
    Medical condition: Advanced or metastatic clear cell renal cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10038416 Renal clear cell carcinoma LLT
    16.1 100000004864 10009251 Clear cell carcinoma of the kidney LLT
    16.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-007460-22 Sponsor Protocol Number: C-100-27 Start Date*: 2008-04-01
    Sponsor Name:Antigenics Inc.
    Full Title: International Survival Follow-up of Patients Enrolled In the Renal Cell Carcinoma Evaluation of Adjuvant Oncophage® Treatment in the Antigenics C-100-12 (Part I) Protocol (INSPIRE).
    Medical condition: Renal cell carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038395 Renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) AT (Ongoing) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000589-47 Sponsor Protocol Number: 3475-427 Start Date*: 2016-09-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)
    Medical condition: Renal cell carcinoma (clear cell & non-clear cell), or kidney cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) ES (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000473-23 Sponsor Protocol Number: RETRY Start Date*: 2012-05-29
    Sponsor Name:GIOM - Gruppo Italiano Oncologia Nefrologica
    Full Title: PHASE II STUDY OF SUNITINIB AS RECHALLENGE THIRD-LINE THERAPY IN METASTATIC RENAL CANCER
    Medical condition: Metastatic renal cancer thrid-line therapy already treated in fist-line therapy with Sunitinib.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009251 Clear cell carcinoma of the kidney LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000493-56 Sponsor Protocol Number: PIM4973g Start Date*: 2011-09-15
    Sponsor Name:GENENTECH, Inc.
    Full Title: A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0980 VERSUS EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE PROGRESSED ON OR FOLLOWING VEGF-TARGETED THERAPY
    Medical condition: METASTATIC RENAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038409 Renal cell carcinoma NOS LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000619-17 Sponsor Protocol Number: NAXIVA1.0 Start Date*: 2017-08-02
    Sponsor Name:Common Services Agency (CSA)
    Full Title: Phase II neoadjuvant study of Axitinib for reducing extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion.
    Medical condition: Venous tumour thrombus in clear cell renal cell cancer with venous invasion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-000425-45 Sponsor Protocol Number: Start Date*: 2012-07-03
    Sponsor Name:
    Full Title: Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib.
    Medical condition: Renal Cell Cancer, GIST, pancreatic neuroendocrine tumor
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055008 Gastric sarcoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003167-58 Sponsor Protocol Number: WO29074 Start Date*: 2014-04-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CAR...
    Medical condition: ADVANCED RENAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) IT (Completed) GB (Completed) ES (Completed) FR (Completed) RO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000928-71 Sponsor Protocol Number: GOIRC02/2008-TWIST Start Date*: 2008-11-14
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: “TWIST”. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008
    Medical condition: Patients with advanced non-clear Cell Renal Carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    9.1 10038458 Renal granular cell carcinoma PT
    9.1 10038414 Renal cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000502-29 Sponsor Protocol Number: WO41994 Start Date*: 2020-09-01
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERAB...
    Medical condition: Renal cell carcinoma (RCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038395 Renal carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038400 Renal carcinoma stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) GR (Completed) PL (Trial now transitioned) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003065-15 Sponsor Protocol Number: VEG115232 Start Date*: 2013-04-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib
    Medical condition: advanced or metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-000353-38 Sponsor Protocol Number: WX-2003-07-HR Start Date*: 2004-12-20
    Sponsor Name:Wilex AG
    Full Title: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence
    Medical condition: Renal cell carcinoma of the clear cell type after nephrectomy and no evidence of residual disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) ES (Ongoing) GB (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022589-29 Sponsor Protocol Number: EP-TSC-624 Start Date*: 2011-03-22
    Sponsor Name:University of Oxford
    Full Title: Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Everolimus or Rapamycin in renal cancer
    Medical condition: Renal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001113-14 Sponsor Protocol Number: TEM-IIG-2 Start Date*: 2011-12-20
    Sponsor Name:Fundación Hospital Clinic i Provincial
    Full Title: Pharmakokynetic and Pharmacodynamic study of Temsirolimus in Renal Cell Carcinoma Patients
    Medical condition: Renal Cell Carcinoma Patients
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000777-38 Sponsor Protocol Number: SOAP Start Date*: 2014-06-19
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: Activity and safety of second line SOrafenib After Pazopanib in patients with metastatic renal cell carcinoma (SOAP Study)
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001316-38 Sponsor Protocol Number: UR1909 Start Date*: 2019-11-20
    Sponsor Name:Department of Oncology, Herlev University Hospital
    Full Title: A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
    Medical condition: Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066352 Renal cell carcinoma with sarcomatoid features LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078493 Papillary renal cell carcinoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029508 Non-renal cell carcinoma of kidney NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005658-37 Sponsor Protocol Number: 2006-1 Start Date*: 2006-07-07
    Sponsor Name:Dpt. of Urology -K. Aarhus University Hospital
    Full Title: A randomized, multi-center study to assess the effect of Darbepoetin alfa (Aranesp®) for the treatment of anemia in patients with advanced hormone independent prostate cancer and anaemia
    Medical condition: In an open randomised, multi-center study to identify the haematopoietic response to Aranesp® (Darbepoetin 6,75 mcg/kg) administrated every fourth week compared to standard care of treatment in pat...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038444 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004751-38 Sponsor Protocol Number: om 174 Start Date*: 2004-02-11
    Sponsor Name:OSPEDALE ONCOLOGICO DI BARI
    Full Title: Vaccine with dendritic cells pulsed tumoral cell line or with autologue tumor in patients with kidney carcinoma
    Medical condition: kidney carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038415 PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:26:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA